Ventana Biotech, Inc. (VNTAD) Announces Name Change to Ventana Global, Inc. and Significant Outstanding Share Reduction
Ventana Biotech (VNTAD) announced its name change to Ventana Global, Inc. along with a significant share restructuring through a 1-for-20 reverse stock split effective January 14, 2025. The company has reduced its authorized shares from 3 billion to 500 million, while outstanding shares decreased from approximately 1.08 billion to 53.78 million.
The ticker symbol will temporarily remain as VNTAD until mid-February 2025, when it will change to VNTA. According to CEO Stephen Replin, these changes reflect the company's expanded strategic vision and aim to create a more investor-friendly capital structure. The name change also addresses marketplace confusion about the company's biotech focus, as it plans to pursue broader global business opportunities.
Ventana Biotech (VNTAD) ha annunciato il cambiamento del suo nome in Ventana Global, Inc. insieme a una significativa ristrutturazione azionaria attraverso uno stock split inverso 1-per-20, che entrerà in vigore il 14 gennaio 2025. L'azienda ha ridotto le sue azioni autorizzate da 3 miliardi a 500 milioni, mentre le azioni in circolazione sono diminuite da circa 1,08 miliardi a 53,78 milioni.
Il simbolo del ticker rimarrà temporaneamente VNTAD fino a metà febbraio 2025, quando cambierà in VNTA. Secondo il CEO Stephen Replin, questi cambiamenti riflettono la visione strategica ampliata dell'azienda e mirano a creare una struttura di capitale più favorevole per gli investitori. Il cambiamento del nome affronta anche la confusione del mercato riguardo al focus biotecnologico dell'azienda, poiché intende perseguire opportunità commerciali globali più ampie.
Ventana Biotech (VNTAD) anunció su cambio de nombre a Ventana Global, Inc. junto con una reestructuración significativa de las acciones a través de un split inverso de 1 por 20, que será efectivo el 14 de enero de 2025. La compañía ha reducido sus acciones autorizadas de 3 mil millones a 500 millones, mientras que las acciones en circulación disminuyeron de aproximadamente 1.08 mil millones a 53.78 millones.
El símbolo del ticker permanecerá temporalmente como VNTAD hasta mediados de febrero de 2025, cuando cambiará a VNTA. Según el CEO Stephen Replin, estos cambios reflejan la visión estratégica ampliada de la empresa y tienen como objetivo crear una estructura de capital más favorable para los inversionistas. El cambio de nombre también aborda la confusión del mercado sobre el enfoque biotecnológico de la empresa, ya que planea buscar oportunidades comerciales globales más amplias.
Ventana Biotech (VNTAD)는 이름을 Ventana Global, Inc.로 변경한다고 발표하며, 2025년 1월 14일부터 1대 20의 역주식 분할을 통한 주식 재구성을 진행합니다. 이 회사는 승인된 주식 수를 30억 주에서 5억 주로 줄였고, 유통 주식 수는 약 10억 8천만 주에서 5천 378만 주로 감소했습니다.
티커 기호는 2025년 2월 중순까지 임시로 VNTAD로 유지되며, 그 이후에는 VNTA로 변경됩니다. CEO 스티븐 렙린에 따르면, 이러한 변화는 회사의 확장된 전략적 비전을 반영하며, 투자자 친화적인 자본 구조를 만들기 위한 것입니다. 이름 변경은 회사의 생명공학 중심에 대한 시장의 혼란을 해소하기 위한 것이며, 더 넓은 글로벌 비즈니스 기회를 추구할 계획입니다.
Ventana Biotech (VNTAD) a annoncé son changement de nom en Ventana Global, Inc. ainsi qu'une restructuration importante de ses actions à travers une division inversée de 1 pour 20, qui prendra effet le 14 janvier 2025. L'entreprise a réduit ses actions autorisées de 3 milliards à 500 millions, tandis que les actions en circulation ont diminué d'environ 1,08 milliard à 53,78 millions.
Le symbole du ticker restera temporairement VNTAD jusqu'à la mi-février 2025, où il sera changé en VNTA. Selon le PDG Stephen Replin, ces changements reflètent la vision stratégique élargie de l'entreprise et visent à créer une structure de capital plus favorable aux investisseurs. Le changement de nom répond également à la confusion du marché concernant l'orientation biotechnologique de l'entreprise, car elle prévoit de poursuivre des opportunités commerciales globales plus larges.
Ventana Biotech (VNTAD) gab die Umbenennung in Ventana Global, Inc. sowie eine wesentliche Umstrukturierung der Aktien durch einen 1-zu-20-Rückwärtssplit bekannt, der am 14. Januar 2025 wirksam wird. Das Unternehmen hat die autorisierten Aktien von 3 Milliarden auf 500 Millionen reduziert, während die ausstehenden Aktien von etwa 1,08 Milliarden auf 53,78 Millionen gesenkt wurden.
Das Tickersymbol bleibt vorübergehend als VNTAD bis Mitte Februar 2025 und wird dann in VNTA geändert. Laut CEO Stephen Replin spiegeln diese Veränderungen die erweiterte strategische Vision des Unternehmens wider und zielen darauf ab, eine investorenfreundlichere Kapitalstruktur zu schaffen. Die Namensänderung soll auch die Verwirrung auf dem Markt hinsichtlich des biotechnologischen Schwerpunkts des Unternehmens adressieren, da es plant, breitere globale Geschäftsmöglichkeiten zu verfolgen.
- Significant reduction in share count potentially improving stock marketability
- Authorized shares reduced by 83.3% from 3B to 500M
- Outstanding shares reduced by 95% from 1.08B to 53.78M
- Reverse stock split might be perceived negatively by market
- Unclear new business direction after moving away from biotech focus
Posturing for future growth!
Denver, Colorado--(Newsfile Corp. - January 29, 2025) - Ventana Biotech, Inc. ("Ventana" or the "Company") today announced that it has changed its name to Ventana Global, Inc. (OTC Pink: VNTAD) from Ventana Biotech, Inc. Concurrently with the name change, the Company has significantly reduced its authorized and outstanding shares as the result of a 1 for 20 reverse stock split which was effective January 14, 2025.
The name change reflects the Company's evolving strategic focus and its intention to pursue a broader range of global business opportunities.
Authorized Shares: The Company has reduced its authorized shares from 3,000,000,000 to 500,000,000.
Outstanding Shares: Effective January 14, 2025, the Company has reduced its outstanding shares from 1,075,665,990 shares to approximately 53,783,299 (not reflective of fractional shares), as the result of the reverse stock split.
Trading Symbol: VNTAD until mid-February when the ticker symbol becomes VNTA.
"Both the change of name, and outstanding share reduction initiatives mark significant steps forward for the development of Ventana Global, Inc," stated Stephen Replin, President and CEO of the Company.
He continued stating "Further, we believe that this new capital structure, and change of name, will enable us to pursue corporate opportunities that may have been unavailable to us as Ventana Biotech, Inc. more easily."
"These actions align our corporate identity with our expanded strategic vision and have been done to create a more robust and investor-friendly capital structure for our long-term growth. With an adjustment to the number of outstanding shares, we are well-positioned to pursue strategic growth opportunities and enhance shareholder value more easily."
The president also stated that "the marketplace confusion suggesting that the Company is involved in the biotech industry as the result of its former name will no longer be a factor to the perception of our business focus in the view of 3rd parties. This additional simplification adds to our vision for the growth of the Company."
About Ventana Global, Inc.
Ventana Global, Inc. is currently in the business of servicing a portfolio of loans. Additionally, the Company has formed and is developing a consulting program that will provide services to third party businesses and individuals. The consulting subsidiary of LaunchPad Cafe, Ltd. (itself a wholly owned subsidiary of Ventana Global, Inc.) is named MPM Business Group, LTD.
The Company also has a division of LaunchPad Café, Ltd entitled LaunchPad Hot Sauces, LTD which has entered a drop shipping/affiliate arrangement with the manufacturer of a line of hot sauces. This drop-shipping arrangement does not require the Company to carry inventory or fulfill orders. LaunchPad Hot Sauces, LTD will be compensated by being paid a percentage of the gross sales volume attributable to the Company.
Neither division has generated revenues for Ventana since its formation as of this date.
Contact Information:
Ventana Global, Inc.
Stephen Replin, CEO
(303) 916-9676
sreplin@gmail.com
Cautionary Statement Concerning Forward-Looking Statements:
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements represent the Company's expectations or beliefs concerning future events and can generally be identified by the use of statements that include words such as "estimate," "project," "believe," "anticipate," "shooting to," "intend," "plan," "foresee," "likely," "will," "would," "appears," "goal," "target" or similar words or phrases. Forward-looking statements include, but are not limited to, statements regarding the Company's expectations for revenue growth and new customer and business opportunities. These forward-looking statements are subject to risks, uncertainties, and other factors, many of which are outside of the Company's control, that could cause actual results to differ materially from the results expressed or implied in the forward-looking statements, including, among others: the lack of capital to pursue expansion activities, and as the result, the Company's ability to compete against new and existing competitors is limited; its ability to identify and move forward with acquisition targets; and the Company's ability to attract and retain qualified personnel to direct this anticipated growth. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or the future performance of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. The Company expressly disclaims any intent or obligation to update any of the forward-looking statements made in this release or in any of its filings except as may be otherwise stated by the Company.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/238817
FAQ
What is the new share count for VNTAD after the 1-for-20 reverse split in January 2025?
When will VNTAD's ticker symbol change to VNTA?
How many authorized shares does Ventana Global have after the January 2025 reduction?
Why did Ventana Biotech change its name to Ventana Global in 2025?
